Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of STSP-0601 in Hemophilia A or B
NCT05619926Phase 2Completed
- Sponsor
- Staidson Biopharmaceutical
- Start
- Jan 2023
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of bemiltenase alfa in hemophilia A and hemophilia B (HB) (2 arms), sponsored by Staidson Biopharmaceutical. Primary endpoints: Incidence of adverse events and Proportion of successfully treated bleeding episodes at 8 hours. Started Jan 2023; status: completed.
02
Drugs
bemiltenase alfa
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT05619926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05619926.